AstraZeneca still waiting for FDA decision to resume U.S. trial-CEO
FRANKFURT, Sept 24 (Reuters) - AstraZeneca AZN.L is still waiting for the go-ahead from the U.S. drug regulator to restart the clinical trial of its COVID-19 vaccine hopeful in the United States, Chief Executive Pascal Soriot said on Thursday.
"We are awaiting to hear their decision," Soriot told a virtual World Economic Forum discussion.
(Reporting by Ludwig Burger Editing by Caroline Copley)
((Caroline.Copley@thomsonreuters.com; +49 (0)30 2201 33584 ;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
In This Story
AZNLatest Markets Videos
Explore US Markets
ExploreMost Popular
- Tesla removed from S&P 500 ESG index on autopilot, discrimination concerns
- Fed could cut rates in 2023, 2024 once inflation under control -Bullard
- US STOCKS-Wall Street ends sharply lower as Target and growth stocks sink
- Powell says Fed to 'keep pushing' rates higher until clear inflation is falling